criterion is clinician-judged HF. In the registry, ≈80 variables are recorded at discharge from hospital or after outpatient clinical visit on a case record form and entered into a central web-based database. The protocol, registration form, and annual report are available at http:// www.rikssvikt.se. The establishment of the registry and registration and analysis of data were approved by a multisite ethics committee. Individual patient consent was not required, but patients were informed of entry into clinical registries and allowed to opt out. The registry and this study conform to the Declarations of Helsinki.
Between May 11, 2000, and May 11, 2012 , there were 46 959 unique registrations (Figure 1 ) from 66 out of 77 hospitals and 96 out of 1011 primary healthcare centers in Sweden.
Cut-Off Level of Ejection Fraction
The cut-off in ejection fraction (EF) to define HFPEF is controversial and has been discussed in the literature. 25 We chose EF ≥50% for the primary analysis. However, many publications have defined HFPEF as EF ≥40%, which among other studies is used in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM)-Preserved study 26 and in a subgroup analysis of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trial 14 ; therefore, we provided a separate analysis on EF 40% to 49% (Appendix in the Data Supplement).
Use of Statins
The use of statins was defined as prescribed by physician at time of discharge from hospital or outpatient visit.
Outcomes
The Swedish National Board of Health and Welfare (http://www. socialstyrelsen.se) keeps records of cause of death in the Cause of Death Registry and of hospitalizations and their causes in the Patient Registry. These databases were extracted with data until December 31, 2011 . For cardiovascular mortality and hospitalization, we included the International Classification of Diseases v. 10 diagnoses I00-I99.
Statistical Analysis
Descriptive data are presented as numbers (n) and percentages or means with standard deviation or median with interquartile range as appropriate. For comparison of continuous variables, we used Student's unpaired t test, whereas the χ 2 test was used for discrete variables.
Propensity Scores
Propensity scores for treatment with statins were estimated for each patient by use of logistic regression with 40 clinically relevant baseline variables (all numbered variables indicated in Table 1 ) as independent variables and statin treatment as the dependent variable. All continuous variables were modeled using restricted cubic splines (3 degrees of freedom). The propensity score is the propensity from 0 to 1 to receive treatment given a set of known variables and is used to adjust for potential selection bias, confounding and differences between treatment group in observational studies. 27, 28 Missing values were handled by estimating one logistic regression model for each pattern of missing values. Each individual then received the propensity score that incorporated all variables with nonmissing values for that individual. An age-and propensity scorematched population was constructed 29 with matching 1:1 without replacement, based on age difference ≤5 years and propensity score difference ≤0.1. This yielded 2074 patients in each group.
Outcomes
In the overall population, crude survival by statin treatment was assessed with Kaplan-Meier analyses and plotted in the same figure as Kaplan-Meier survival for the matched population ( Figure 2 ). Cox regression models were used to estimate the hazard ratio (HR) and corresponding 95% confidence interval (CI) in the overall population, crude as well as in the matched population. The dependence between matched pairs was modeled within the Cox regression by adding a frailty term assuming a Gaussian distribution. 30 The proportional hazards assumption was tested by scaled Schoenfeld residuals, and the presence of extreme outliers was assessed by dfbetas. No violations to the proportional hazards assumption or possible influential outliers were found.
Interactions between statin therapy and clinically relevant variables were modeled with Cox regression and presented in a Forest plot for all-cause mortality for the matched population ( Figure 3 ). Continuous variables were categorized for easier visual interpretation. Interaction analyses render similar results as subgroup analyses, with the additional benefit of being able to statistically test for differences in association between statin use and outcomes between subgroups.
In addition to all-cause mortality, we also assessed cardiovascular mortality and a composite end point of time to all-cause mortality or cardiovascular hospitalization. The definition of cardiovascular mortality and cardiovascular hospitalization was based on the ICD codes as presented above. Patients not experiencing an event were censored on December 31, 2011. Additionally, for the end point cardiovascular mortality, censoring also occurred if the patient died from other causes.
For all analyses, a level of significance was set to 5%, and all reported P values are 2-sided. All statistics were performed in R v 3.1.3 (R foundation for Statistical Computing, Vienna, Austria).
Results

Patients
Baseline characteristics of the overall and the matched populations are presented in Table 1 . The final population consisted of 9140 patients after exclusion of those with missing information, with EF <50%, or included in the registry after December 31, 2011, the latter because of lack of cause-specific outcomes ( Figure 1 ). Among 9140 patients with HFPEF, mean age was 77 years (SD, 11), proportion of female patients was 54.0%, and 3427 (37.5%) were treated and 5713 (62.5%) were not treated with statins. In the overall population, differences could be seen in many variables, indicating that the 2 populations could not be directly compared.
Patients treated with statins were younger (75 versus 78 years), were more often males (52.1% versus 42.4%), had a higher proportion of diabetes mellitus (35.3% versus 18.6%), and had a higher proportion of IHD (58.7% versus 25.3% not on statins). However, after matching for propensity score and age, the differences between the groups were considerably reduced or eliminated. The differences in propensity scores between the matched groups were therefore small, and the standard differences were ≤10% for all variables, including important potential confounders, such as age, IHD, hypertension, renal function, level of NT-proBNP, and hemoglobin, which is considered to represent good matching. 31 The only variable with a standardized difference >10% was use of nitrates (11%), which was larger in the statin group.
Mortality Outcomes
In the overall population, 1-year survival was 87.2% (95% CI, 86.0%-88.4%) in the statin group versus 76.3% (95% CI, 75.1%-77.4%) in the nonstatin group. After 3 years, the HCM, n (%) 17 P value is comparison of the differences between the groups using t test for continuous variables and the χ 2 test for categorical variables. Mean arterial pressure is derived as systolic blood pressure×one-third plus diastolic blood pressure×two thirds. No. indicates the variables included in the derivation of the propensity score. ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; BMI, body mass index; DCM, dilated cardiomyopathy; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; IHD, ischemic heart disease; NT-proBNP, N-terminal fragment of proBNP; NYHA class, New York Heart Association functional class; stand diff, standardized difference-the difference between the means for the two groups divided by the mutual standard deviation. (Figure 2 ). In the matched population, 1-year survival was 85.1% (95% CI, 83.5%-86.7%) in the statin group versus 80.9% (95% CI, 79.2%-82.7%) in the nonstatin group. The hypothetical number needed to treat for 1 year to prevent one death from any cause was 29. After 3 years, survival was 66.1% (95% CI, 63.8%-68.6%) versus 61.3% (95% CI, 58.9%-63.8%), and number needed to treat was 16; after 5 years, the corresponding figures were 52.9% (95% CI, 49.8%-56.2%) versus 45.0% (95% CI, 41.7%-48.5%), and number needed to treat was 23 ( Figure 2) .
In Cox regressions, the HRs (95% CI) for the association between statin use and all-cause mortality was 0.59 (95% CI, 0.55-0.63; P<0.001) in crude analysis in the overall population and 0.80 (95% CI, 0.72-0.89; P<0.001) in the matched population ( Table 2) . Figure 3 shows a Forest plot illustrating the association between statin use and all-cause mortality in different subgroups for the matched population. There were no statistically significant interactions.
Secondary Outcomes
Regarding the secondary outcomes in the matched population, HRs associated with statin use were as follows: for cardiovascular mortality, HR was 0.86 (95% CI, 0.75-0.98; P=0.026), and for composite all-cause mortality or cardiovascular hospitalization, HR was 0.89 (95% CI, 0.82-0.96; P=0.003).
Analysis of Group With EF 40% to 49%
As there has been controversy in the literature regarding definition of HFPEF and because previous randomized trial included primarily EF <40%, we also performed analyses of the group with HFPEF and EF 40% to 49% (Appendix in the Data Supplement). The results were similar in the EF 40% to 49% groups compared with EF ≥50% groups. There was no statistically significant interaction between statin use and IHD, but the point estimate was toward greater risk reduction in patient with IHD.
Discussion
The potential role of statins in patients with HFPEF is unknown. Therefore, we analyzed one of the largest HF registries in the world, the Swedish Heart Failure Registry (RiksSvikt), and specifically evaluated the association between statin treatment and outcomes in patients with HFPEF.
Statin use was associated with reduced all-cause mortality in HF with EF ≥50%, with an HR of 0.80. A hypothetical number needed to treat to save one life over one year was 29 in the propensity score-matched analysis. Statin use was also associated with reduced cardiovascular mortality and a reduction in the combined end point of all-cause mortality or cardiovascular hospitalization. Results were similar in HF with EF 40% to 49%.
Possible Mechanisms of Statin Benefits
The exact mechanism of the potential statin benefit in HFPEF function is unknown, but there are some interesting data that might support our findings. Paulus and Tschöpe suggest that the mechanisms behind HFPEF may be related to comorbidities (hypertension, obesity, diabetes mellitus, and chronic obstructive pulmonary disease) and the systemic and microvascular inflammation induced by these comorbidities. 22 As a result, cardiomyocytes are exposed to less nitric oxide because the production of reactive oxygen species is increased by vascular endothelial cells. This results in cardiomyocyte hypertrophy and interstitial fibrosis, leading to increased stiffness of the myocardium, as well as increased resting tension, which is indeed seen in patients with HFPEF. 22, 32, 33 There was no interaction between statin use and IHD or diabetes mellitus. This is consistent with the theory that HFPEF may represent a systemic proinflammatory state independent of these risk factors, 22 that is, in our patients, statins may have reduced this inflammation rather than having an effect on atherosclerosis or macrovascular disease per se.
That there is an increased inflammatory activity in HFPEF is discussed in several publications, [34] [35] [36] even if the exact mechanism is not clear. In the present study, subgroups with increased inflammatory response, like patients with diabetes mellitus, increased age, or IHD, have been evaluated (Figure 3 ). However, there were no statistically significant interaction with statin use and any subgroup. Previous studies have had numerous limitations, but do support our results. In a small propensity score-matched study in HFPEF, Fukuta et al presented data suggesting a positive effect on mortality, despite both groups achieving the same serum lipid levels. 18 A recent meta-analysis including 11 observational studies and 17 985 patients by Liu et al 37 suggested a 40% risk reduction for mortality (95% CI for the HR, 0.49-0.74). However, all of the included studies except for one were small and with a majority including <100 patients per treatment arm. Second, only 3 of the included 11 studies had high quality based on the Newcastle-Ottawa Scale. Finally, there was considerable heterogeneity across the studies.
In a population-based study including >13 500 Medicare beneficiaries with HFPEF by Shah et al, the use of statins was associated with reduced mortality, which persisted when adjusting for potential confounding variables. 20 The positive association with survival was noted irrespective of cholesterol level. We could show the same association with reduced mortality, even though the present population was younger and exhibited lower annual mortality. Finally, Gastelurrutia et al showed in a small study of a mixed population of both HFPEF and HFREF significant reduction of mortality in those on treatment with statins. 38 Thus, it seems that previous studies concur with the results obtained from the present study. The present study does, however, also report on cardiovascular mortality, as well as on all-cause mortality or cardiovascular hospitalization combined, to obtain even more information regarding the effect of statin treatment, adding to the emerging understanding of possible benefits of statins in HFPEF.
This registry-based study should be interpreted in the light of randomized controlled trials (RCTs) and the present guidelines. In the American College of Cardiology/American Heart Association guidelines 2013 on treatment of blood cholesterol to reduce cardiovascular risks, it could be noted that no recommendation of treatment with statins are made to patients in New York Heart Association functional class II-IV. 39 For patients with HFREF, it is stated in the American College of Cardiology/American Heart Association guidelines 2013 on management of HF that statins are not advised because no benefit has been shown. No specific recommendations are given regarding statin treatment in HFPEF. 40 It could be noted, however, that one of the references for this was the RCT presented by Kjekshus et al, where only patients with impaired systolic function were included, and thus, not the type of HF discussed here. 13 Another reference for American College of Cardiology/American Heart Association HF guideline was the GISSI-HF study, where only ≈10% of the included patients had HFPEF, and thus, no subgroup analysis was made for this group. 14 The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-HF studies suggest that statins are not beneficial in HFREF, even in the presence of IHD and diabetes mellitus. However, in an observational study on HFREF from the Swedish Heart Failure Registry parallel to the present study, we observed a strong interaction between statin use and outcomes (HR for mortality, 0.76; 95% CI, 0.70-0.82; P<0.001 in the presence of IHD; HR, 0.95; 95% CI, 0.85-1.07; P=0.43 in the absence of IHD; P for interaction, 0.001). 41 In this study, we raise the possibility that although statins have no role in HFREF without IHD, the potential benefit in IHD may still not be ruled out. In contrast, in the HFPEF population studied here, no such interaction with IHD was observed, with an associated benefit regardless of IHD (P for interaction, 0.741; Figure 3 ). In the EF 40% to 49% group, there was no significant interaction with IHD, but the point estimate was toward greater risk reduction in the presence of IHD, suggesting that the EF 40% to 49% group may represent an interim between HFREF and HF with truly preserved EF. These data are indeed consistent with the hypothesis that HFPEF involves a systematic proinflammatory state with micro-rather than macrovascular dysfunction. However, there are no randomized trials on HFPEF, and as discussed, the pathophysiology of HFPEF may be more amenable to modification by statins. Thus, there is a need for an evaluation of statin treatment in patients with HFPEF. The optimal way would be a large RCT, but as no one yet is performed, the present data are of interest and also hypothesis generating and a strong rationale to perform such a study.
Limitations
Because this is not an RCT, we cannot rule out residual confounding. However, several factors reduce the influence of confounding, like large patient number, long duration of follow-up, extensive covariate availability for generation of and matching, and finally adjustment for propensity scores. Given the complexity of HFPEF and the fact that statins are now generic and inexpensive, a large industry-sponsored trial may be unlikely, but given the high prevalence, poor prognosis, and lack of current therapy, a publicly funded adequately powered RCT of statins in HFPEF would be warranted, perhaps using the novel registry-randomized trial concept. In the registry, 54.0% were females, representative of most, [42] [43] [44] [45] [46] [47] but lower than in some, HFPEF populations.
Some clinical variables are missing in the registry, like type of statin used and dose; C-reactive protein and low-density lipoprotein levels; and other potential confounding medications, such as steroids and nonsteroidal anti-inflammatory drugs. However, the extensive number of covariates covers much of the potential factors that may influence statin use and outcomes independent of statin use.
We did not have access to serum lipid levels. Although many treated patients may have had a dyslipidemia indication, this would likely confound toward worse rather than better outcomes in treated patients. We still cannot rule out that the results are in part a reflection of lipid-lowering effects, but the absence of an interaction with IHD and diabetes mellitus supports a potential effect of statins that is independent of vascular disease.
The information on patient adherence to statin therapy during the follow-up time was not possible to obtain from the registry.
Statin use was reported at baseline only, and crossover may have occurred throughout follow-up, but this would only dilute any potentially associated improvement in outcomes.
The results are based on a HF registry from Sweden. It is not certain that the handling of HF patients is the same in different countries, even if the pharmacological treatments are the same. Thus, some of our results might not be directly transferred into other healthcare systems.
As the study is observational, there is always a potential issue regarding bias and confounding. Therefore, we have performed propensity score matching and adjustment for the variables believed to affect bias or confounding. A standardized difference between groups of ≤10% is generally considered inconsequential. 48 Of all the variables adjusted for, only one had a standardized difference of >10%. However, we cannot rule out existence of unknown or unmeasured variables resulting in residual confounding.
The causes of hospitalization have been validated and found to be accurate in Swedish registries, 49 but cause of death is based on death certificates and notoriously unreliable, 50 and therefore, the outcome cardiovascular mortality should be interpreted with some care. In patients with an indication, nonuse of statins could be because of intolerance or general undertreatment. Use of renin-angiotensin system antagonists and β-blockers was greater in statin-treated patients overall, but after matching, the difference was small. Furthermore, there was no interaction between statin use and diabetes mellitus, coronary disease, or any other subgroup, again suggesting that the favorable association between statins and outcomes in HFPEF was unrelated to these comorbidities.
Conclusions
In patients with HFPEF, the use of statins was associated with reduced all-cause mortality, cardiovascular mortality, and combined all-cause mortality or cardiovascular hospitalization. The mechanisms need to be studied further, and our findings should be tested in an adequately powered RCT.
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